David M. Tanen, Director at Nile Therapeutics, Inc. (NLTX), bought 6,500 shares at $1.04 ($9K) on 2008-12-15, disclosed to the SEC on 2008-12-15.
Open-market purchase of $9k NLTX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.47 | 4,000 | $6K | 69.1% |
| 2 | $1.04 | 20 | $21 | 0.2% |
| 3 | $1.05 | 2,480 | $3K | 30.6% |
| Total | $1.31 avg | 6,500 | $9K | 100% |
| Filing → |
| NLTX | BUY | 2008-12-12 | $3K | — | Filing → |